^
    Back
    Association details:
    Biomarker:HDAC6 expression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:PD1 inhibitor +
    HDAC inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res Treat
    Title:

    Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer

    Published date:
    09/10/2021
    Excerpt:
    ...co-treatment with HDACi and PD-1 inhibitor was shown to decrease the tumor growth rate and create a favorable tumor microenvironment for cytotoxic T lymphocytes in the TC-1 mouse model.
    DOI:
    10.4143/crt.2021.425